T1	Participants 13 42	rheumatoid arthritis patients
T2	Participants 343 401	etanercept-treated patients with rheumatoid arthritis (RA)
T3	Participants 730 795	patients initiating etanercept (monotherapy or with methotrexate)
T4	Participants 966 1035	Patients from TEMPO and RADIUS II who received etanercept monotherapy
T5	Participants 1399 1439	patients with lower baseline CDAI scores
T6	Participants 1883 1922	Patients with lower RA disease activity
T7	Participants 2002 2041	patients who achieved remission earlier
